![Kenneth Mulvany](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kenneth Mulvany
Gründer bei
BENEVOLENTAI S.A.
Profil
Kenneth Patrick Mulvany was the founder of Proximagen Group Ltd. (2005), where the title held was Chief Executive Officer from 2005 to 2012.
Dr. Mulvany was the founder of BenevolentAI SA (2013), holding the title of Non-Executive Director from 2013 to 2022 and Executive Chairman starting in 2024.
Dr. Mulvany was the founder of BenevolentAI Ltd. (2015), serving as Executive Chairman from 2015 to 2021.
Dr. Mulvany currently holds the position of Director at BenevolentAI Bio Ltd. since 2013.
Dr. Mulvany is a Trustee at The Cure Parkinson's Trust.
Dr. Mulvany was a Director at Minster Pharmaceuticals Plc.
Aktive Positionen von Kenneth Mulvany
| Unternehmen | Position | Beginn |
|---|---|---|
| BENEVOLENTAI S.A. | Gründer | - |
BenevolentAI Bio Ltd.
 BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Engages in development and application of artificial intelligence | Direktor/Vorstandsmitglied | 13.11.2013 |
The Cure Parkinson's Trust
 The Cure Parkinson's Trust BiotechnologyHealth Technology Operates as a research org dedicated to finding a cure for Parkinson’s | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Kenneth Mulvany
| Unternehmen | Position | Ende |
|---|---|---|
| BENEVOLENTAI S.A. | Gründer | 30.06.2022 |
Minster Pharmaceuticals Plc
 Minster Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions | Direktor/Vorstandsmitglied | - |
BenevolentAI Ltd.
 BenevolentAI Ltd. Packaged SoftwareTechnology Services Operates as a AI-enabled drug discovery company | Gründer | - |
Proximagen Group Ltd.
 Proximagen Group Ltd. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics designed for the treatment of central nervous system diseases | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
2
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Proximagen Group Ltd.
Proximagen Group Ltd. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics designed for the treatment of central nervous system diseases | Health Technology |
Minster Pharmaceuticals Plc
Minster Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions | Health Technology |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Operates as a AI-enabled drug discovery company | Technology Services |
BenevolentAI Bio Ltd.
BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Engages in development and application of artificial intelligence | Technology Services |
The Cure Parkinson's Trust
The Cure Parkinson's Trust BiotechnologyHealth Technology Operates as a research org dedicated to finding a cure for Parkinson’s | Health Technology |
BenevolentAI SA
 BenevolentAI SA Packaged SoftwareTechnology Services Develops AI drug discovery platform to accelerate biopharma drug discovery | Technology Services |
